A new defect of peroxisomal function involving pristanic acid: a case report

McLean, B.N.; Allen, J.; Ferdinandusse, S.; Wanders, R.J.A.

Published in: Journal of Neurology, Neurosurgery and Psychiatry

DOI: 10.1136/jnnp.72.3.396

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

Download date: 12 Dec 2019
A new defect of peroxisomal function involving pristanic acid: a case report

B N McLean, J Allen, S Ferdinandusse and R J A Wanders

doi:10.1136/jnnp.72.3.396

Updated information and services can be found at:
http://jnnp.bmjjournals.com/cgi/content/full/72/3/396

These include:

References
This article cites 17 articles, 3 of which can be accessed free at:
http://jnnp.bmjjournals.com/cgi/content/full/72/3/396#BIBL

2 online articles that cite this article can be accessed at:
http://jnnp.bmjjournals.com/cgi/content/full/72/3/396#otherarticles

Rapid responses
You can respond to this article at:
http://jnnp.bmjjournals.com/cgi/eletter-submit/72/3/396

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Other Neurology (3640 articles)
Epilepsy (349 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Journal of Neurology, Neurosurgery, and Psychiatry go to:
http://www.bmjjournals.com/subscriptions/
A new defect of peroxisomal function involving pristanic acid: a case report

B N McLean, J Allen, S Ferdinandusse, R J A Wanders

In general, peroxisomal disorders present either at birth with deficits resulting in severe hypotonia and craniofacial dysmorphism or as later onset psychomotor retardation, seizures, and hepatomegaly. There is, however, a considerable range of clinical problems within a disorder and overlap between disorders, so that some can only be differentiated on biochemical grounds.

We present a case of adult onset neurological disease the features of which were reminiscent of a peroxisomal disorder, but in a novel combination.

The biochemical defect has been recently elucidated, and has been shown to be due to a deficiency of α-methylacyl-CoA racemase (AMACR) making our patient one of the first adults to be described with this condition.

CASE REPORT

A 44 year old man presented with failing vision, having been suspected by his general practitioner of malingering.

He was born of non-consanguineous parents, one of six children, his brother and four sisters being in good health. He had left school at the age of 14. He had been a poor scholar with reading difficulties and after leaving had a succession of unskilled jobs from which he was invariably dismissed. At the age of 18 he presented with an encephalitic illness characterised by 3 days of severe headache, nausea, and photophobia, with a single blackout followed by progressive confusion, irrational behaviour, and resulting in coma.

He developed focal seizures, with eye deviation to the left and jerking of the neck muscles, which on one occasion generalised. He had tonic deviation of his eyes to the right, sometimes with slow deviation, bilateral papilloedema, but no other focal neurological signs. He had a mild pyrexia and a neutrophil leucocytosis (13×10^3/l). He underwent cerebral angiography and CSF analysis, including protein estimation, both of which were normal. An EEG showed gross disturbances with generalised slowing and loss of α activity. He required ventilation, but then underwent spontaneous recovery, whereupon he was found to be blind. This was initially suspected to be due to occipital lobe infarction, but pigmentary retinal changes were seen extensively in the periphery of both fundi, and a neuroretinitis was proposed. His EEG improved, but did not return to normal, remaining slowed. Vision slowly recovered, initially with perception of light, then colours, and finally acuity, achieving a distance acuity of 6/12 bilaterally and a reading acuity of N24 right N18 left. A neuropsychometric assessment showed a premorbid verbal IQ of 86, a reading age of 7.5 years, and a long term problem with vision was suspected.

At the age of 22 he developed generalised seizures, only partially controlled with phenobarbital and phenytoin.
A new defect of peroxisomal function involving pristanic acid

RESULTS

Full blood count, differential count, urea, electrolytes, liver and bone profiles, thyroid function, glucose, B12 and folate, VDRL, TPHA, protein electrophoresis, and immunoglobulin concentrations were all normal or negative. Cholesterol was borderline low at 3.4 mmol/l (normal 3.5 – 5.2).

Testosterone was 3.2 nmol/l (normal 9–38), estradiol <30 pmol/l (normal 40–185 ), FSH 34.1 IU/l (normal 1.1–7.8), and LH 10.8 IU/l (1.1–9.4) confirming primary gonadal failure. Prolactin was normal.

Chromosomal analysis showed a normal male karyotype. Mitochondrial DNA analysis was negative for MELAS 3243, 3271, 8344 deletions.

The EEG showed occipital slowing with no seizure activity or photoconvulsive response. Visually evoked potentials were abnormal bilaterally with low amplitude disrupted wave forms. Brain stem auditory evoked potentials were normal with N1-N5 latencies of 3.3 ms left, 3.96 ms right. Brain MRI showed minor cerebral atrophy only with normal white matter. Chest radiography was normal. Nerve conduction studies shows a peripheral symmetric sensory motor axonal neuropathy.

DISCUSSION

Our patient had learning difficulties and his psychometric testing as an adult after his encephalitic illness suggested a longstanding premorbid problem with functional and language skills. Encephalitis illnesses have not been noted as a feature of peroxisomal disorders, although Goldman et al described a patient with Refsum’s disease who had an acute onset of ataxia after a viral illness—our patient was initially thought to have had a viral illness with pyrexia. Minor surgery may precipitate deterioration, so it could be postulated that oxidative stresses triggered decompensation or release of phytic acid from fat stores as a result of catabolic stress. The association with encephalopathy we presume to be genuine, but coincidence cannot be excluded.

A comparison of his clinical features with those found in the other peroxisomal disorders shows a general similarity to those of late onset, particularly Refsum’s disease and in common with the single enzyme deficits, there are mild dysmorphic features, he has a seizure disorder with a peripheral neuropathy, no ataxia, a retinopathy and hypogonadism. His brain MRI did not show white matter abnormalities, as

---

**Table 1** Results of fatty acid and bile acid analysis from serum

<table>
<thead>
<tr>
<th>Fatty acid profile</th>
<th>Value found</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLCFA profile:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C26 (µmol/l)</td>
<td>0.53</td>
<td>(0.33–1.39)</td>
</tr>
<tr>
<td>C26/C22</td>
<td>0.008</td>
<td>(&lt;0.030)</td>
</tr>
<tr>
<td>C24/C22</td>
<td>0.58</td>
<td>(0.32–0.92)</td>
</tr>
<tr>
<td>Phytic acid (µmol/l)</td>
<td>20</td>
<td>(&lt;12.8)</td>
</tr>
<tr>
<td>Pristanic acid (µmol/l)</td>
<td>105</td>
<td>(&lt;3.0)</td>
</tr>
<tr>
<td>Pristanic/pyrantic</td>
<td>5.25</td>
<td>(0.05–0.40)</td>
</tr>
<tr>
<td>Bile acid profile (µmol/l):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deoxycorticolic acid</td>
<td>0.02</td>
<td>(&lt;6.4)</td>
</tr>
<tr>
<td>Cheno-deoxycorticolic acid</td>
<td>0.22</td>
<td>(0.27–12.4)</td>
</tr>
<tr>
<td>Cholic acid</td>
<td>0.44</td>
<td>(0.05–4.60)</td>
</tr>
<tr>
<td>Ursodeoxycorticolic acid</td>
<td>0.00</td>
<td>(&lt;2.1)</td>
</tr>
<tr>
<td>Hyocholic acid</td>
<td>0.00</td>
<td>(&lt;1.0)</td>
</tr>
<tr>
<td>Dihydroxycholestanolic acid</td>
<td>0.11</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>Trihydroxycholestanolic acid</td>
<td>2.90</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>Dihydroxycholestanoic acid</td>
<td>0.00</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>C29 dicarboxylic acid</td>
<td>0.01</td>
<td>(not detectable)</td>
</tr>
</tbody>
</table>

---

**Table 2** Results from fibroblast studies

<table>
<thead>
<tr>
<th>Patient</th>
<th>De novo plasmalogens biosynthesis: DHAPAT activity: Pristanic acid β-oxidation activity* AMACR activity†</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>Pristanic acid β-oxidation activity* AMACR activity†</td>
<td>1147 (SD 325) (n=30) 92 (SD 30) (n=11)</td>
</tr>
</tbody>
</table>

* pmol/h/mg protein; † pmol/min/mg protein.
ND, Not detectable. AMACR, α-methylacyl-CoA racemase.
For methods see Ferdinandusse et al.16
seen in adrenomyeloneuropathy, nor neuronal migration deficits as seen in a postmortem of infantile Refsum’s disease.\(^3\) The biochemical defect causing Refsum’s disease lies “upstream”, yet the clinical phenotype of the disorders differ, although with considerable overlap. Why there should be this distinction is uncertain, but there may be a differential effect on tissues depending on the proportions of product accumulation (phytanic and pristanic acid and bile acid intermediates), or loss of lipid functions “downstream”.

In humans, the only peroxisomal disorders of \(\beta\)-oxidation so far identified are those relating to VLCS, DHCA/THCA, and pristanic acid. Multiple enzymes are involved (fig 1) and abnormalities of pristanic acid metabolism were first associated with generalised peroxisomal disorders.\(^3\)

This currently described patient showed highly increased pristanic acid concentrations and mildly raised phytanic acid and VLCFA concentrations. Had the pristanic acid concentrations and mildly raised phytanic acid not been measured, the condition would have been overlooked. Analysis of both enzymes is required to establish the precise defect.

He therefore has a unique combination of features, distinct from the other peroxisomal disorders, but with many features in common, particularly with Refsum’s disease. His disease course has been relatively benign. Presumably this is autosomal recessive as are most of the other peroxisomal disorders, but his family have refused blood testing and skin biopsy. The presence of hypogonadism does raise the possibility of an X linked disorder, but we have been made aware of a woman with the condition (personal communication), so this seems unlikely.

Given that Refsum’s disease responds to dietary elimination of phytanic acid,\(^1\) therapy for this disorder was attempted using a pristanic acid and phytanic acid depleted diet, but he would not tolerate the dietary change. His seizures have remained controlled on phenytoin alone, and there has been no significant progression in his visual failure or neuropathy over 2 years.

As biochemical and molecular biological techniques advance, further peroxisomal disorders are likely to emerge. Recently, another novel disorder of peroxisomes has been described, with multiple enzyme deficiencies (reduced lindsayaric acid oxidation, cytosol catalase only, reduced di-hydroxyacetone phosphate acyl transferase, and reduced phytanic acid oxidation) and normal peroxisomes as in type 2 disorders, but clinically a mixed type 1 and 3 (an adult with facial deformity, cognitive impairment, retinal pigmentation, seizures, and deafness without liver problems).\(^5\)

These overlapping clinical syndromes highlight the importance of wider screening of biochemical function using plasma VLCFA/C26 ratio, but we have been made aware of a woman with the condition (personal communication), so this seems unlikely.

Figure 1 The peroxisomal \(\beta\)-oxidation pathway, showing the steps involved in the oxidation of pristanic acid and THCA/DHCA. The site of activity of AMACR, where the defect occurs in this disorder, is indicated. *
A new defect of peroxisomal function involving pristanic acid

J Allen, Department of Clinical Biochemistry, Southmead Hospital, Bristol BS10 5NB, UK
S Ferdinandusse, R JA Wanders, Laboratory of Genetic Metabolic Diseases, Emma Children’s Hospital AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Correspondence to: Dr B N McLean, Department of Neurology, Royal Cornwall Hospital, Treliske, Truro, Cornwall TR1 3JU, UK

Received 12 September 2000
In revised form 26 September 2001
Accepted 23 October 2001

REFERENCES